Inactive Instrument

News Acura Pharmaceuticals, Inc. Nasdaq

Equities

US00509L8028

Summary

We are working hard...

We are working hard to come back as soon as possible.
Nous travaillons dur pour revenir au plus vite.
Wir arbeiten hart daran, so schnell wie möglich zurückzukommen
Estamos trabajando duro para volver lo antes posible.
Stiamo lavorando sodo per tornare il prima possibile.
Wij werken hard om zo snel mogelijk weer terug te zijn.

Acura Pharmaceuticals : TO LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT - Form 8-K	Mar. 26	PU
Acura Pharmaceuticals, Inc. Announces Amendment to the Agreement with Abuse Deterrent Pharma, LLC	Mar. 26	CI
Acura Pharmaceuticals, Inc. announced that it has received $0.25 million in funding from Abuse Deterrent Pharma, LLC	Mar. 13	CI
Acura Pharmaceuticals, Inc. Receives $250,000 Loan from Abuse Deterrent Pharma, LLC	Feb. 14	CI
Acura Pharmaceuticals, Inc. announced that it has received $0.25 million in funding	Feb. 13	CI
Acura Pharmaceuticals : AMENDED, CONSOLIDATED AND RESTATED SECURED PROMISSORY NOTE - Form 8-K	Dec. 21	PU
Acura Pharmaceuticals, Inc. and Abuse Deterrent Pharmaceuticals, LLC Enter into Amendment #1 to the November 10, 2022 Amended, Consolidated and Restated Secured Promissory Note	Dec. 21	CI
Acura Pharmaceuticals : New Financial Obligation - Form 8-K	Dec. 06	PU
Acura Pharmaceuticals, Inc. Announces Retirement and Resignation of Mr. Bruce F. Wesson as Member of Board of Directors	23-09-25	CI
Acura Pharmaceuticals, Inc. Provides Update Related to LTX-03 (Hydrocodone Bitartrate and Acetaminophen) Tablets	23-08-31	CI
Acura Pharmaceuticals, Inc. Announces Preliminary Topline Results from Study AP-LTX-311 Successfully Demonstrated That A Nine-Tablet Dose of Ltx-03	23-08-30	CI
Acura Pharmaceuticals : Termination of Material Agreement - Form 8-K	23-08-16	PU
Acura Pharmaceuticals, Inc. and Zyla Life Sciences, LLC Agree to Terms for the Termination of the Collaboration and License Agreement	23-08-16	CI
Acura Pharmaceuticals, Inc. Receives $250,000 Loan from Abuse Deterrent Pharma, LLC	23-07-28	CI
Acura Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	23-06-30	CI
Acura Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2021	23-06-30	CI
Acura Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt	23-06-29	CI
Acura Pharmaceuticals : TO LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT - Form 8-K	23-06-28	PU
Acura Pharmaceuticals, Inc. Enters into an Agreement to Further Amend the June 28, 2019 License, Development and Commercialization Agreement with Abuse Deterrent Pharma, LLC	23-06-28	CI
Acura Pharmaceuticals, Inc. Receives $150,000 Loan from Abuse Deterrent Pharma, LLC	23-05-26	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

We are working hard...

We are working hard to come back as soon as possible.
Nous travaillons dur pour revenir au plus vite.
Wir arbeiten hart daran, so schnell wie möglich zurückzukommen
Estamos trabajando duro para volver lo antes posible.
Stiamo lavorando sodo per tornare il prima possibile.
Wij werken hard om zo snel mogelijk weer terug te zijn.